GLP-3 RT

GLP-3 RT

Price range: $100.00 through $220.00

Triple Receptor Agonist

SKU: N/A Category:

Triple-Action Metabolic Compound

A triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. Studied in preclinical research for metabolic regulation and body composition. 39-amino acid lyophilized compound for in vitro scientific investigation.

Specifications

Purity
99%+ COA Verified
Form
Lyophilized Powder
Storage
-20°C
Vial Size
10mg

Technical Details

Sequence / Composition GIP / GLP-1 / Glucagon Tri-Agonist
Molecular Weight ~4,500 g/mol
CAS Number N/A
Certificate of Analysis Included with every order
Third-Party Tested HPLC + Mass Spectrometry
Shipping Plain unmarked packaging · 1–2 days
Research Use Only. This product is intended for in vitro laboratory and pre-clinical research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified researchers only.
📦
Packaging
Shipped in sealed, nitrogen-purged vials with tamper-evident caps. Discreet outer packaging on every order.
🧊
Shipping & Storage
Shipped with cold packs where required. Store at -20°C upon receipt. Stable for 24 months when properly stored.
⚗️
Research Use Only
For in vitro and laboratory research only. Not intended for human or veterinary use. Handle per standard lab safety protocols.
🔬
Reconstitution
Reconstitute with bacteriostatic water or sterile saline. Use within 28 days once reconstituted and refrigerate at 4°C.
📄
Documentation
Full Certificate of Analysis included. Batch number, HPLC report, and mass spec data available on request.
🚚
Dispatch
Orders dispatched within 24 hours on business days. Tracked shipping to US addresses. International shipping available.

Peer-Reviewed Research

GLP-3 RT (Retatrutide) - Sources & References

All citations from accredited peer-reviewed journals. No vendor blogs or promotional content.

01
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes
PubMed / New England Journal of Medicine · 2023 - DOI: 10.1056/NEJMoa2306053
Rosenstock J, et al.
View Study →
02
Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
Nature Medicine · 2024 - PMC11271400
View Study →
03
Retatrutide - Pharmacology and Clinical Overview
StatPearls / PubMed Central · 2024 - PMC11486854
View Study →
04
Perceived Benefits of Treatment for Obesity with Retatrutide: Phase 2 Clinical Trial
Obesity Science & Practice · 2025 - PMC12596213
View Study →

Reviews

There are no reviews yet.

Be the first to review “GLP-3 RT”

Your email address will not be published. Required fields are marked *

Related products

Shopping Cart
Scroll to Top